AzTrials
AzTrials

Condition

Triple Negative Breast Cancer Clinical Trials

Studies of triple negative breast cancer, matched by condition name and medical subject headings. Start with those open to enrolment.

1,251 registered studies

Search and filter these trials

In numbers

Open to volunteers
417
Active
560
With results posted
227
All registered
1,251

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 417

  • Triple-negative Breast Cancer

    Reverse Triple Negative Immune Resistant Breast Cancer

    • Recruiting
    • Age: 18 to 70 years
    • Phase 2
    • Injection or infusion

    This is a Phase II, open-label, nine-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, theophylline, mifepristone) with…

    Trial name
    Renaissance (NCT05076682)
    Testing
    Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate
    Where
    China
    Volunteers
    90 people
    Sponsor
    Fudan University
    Can I take part? Renaissance

  • Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer

    Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

    • Recruiting
    • Age: 18 years and older
    • Phase 2
    • Injection or infusion

    About 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast…

    Trial name
    NCT06358573
    Testing
    INT230-6, neoadjuvant immuno-chemotherapy
    Where
    10 sites in France, Switzerland
    Volunteers
    61 people
    Sponsor
    Swiss Cancer Institute
    Can I take part? NCT06358573

  • Triple Negative Breast Cancer

    A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

    • Recruiting
    • Age: 18 years and older
    • Phase 1
    • Injection or infusion

    The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.

    Trial name
    NCT06908928
    Testing
    bulumtatug fuvedotin
    Where
    7 sites in United States
    Volunteers
    52 people
    Sponsor
    Mabwell (Shanghai) Bioscience Co., Ltd.
    Can I take part? NCT06908928

  • Breast Cancer, Breast Carcinoma

    Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

    • Recruiting
    • Age: 18 to 120 years
    • Observational study

    Background: Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or brain. Breast cancer that spreads to the brain is often fatal.

    Conditions
    Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
    Trial name
    NCT07619534
    Testing
    Arm 1
    Where
    United States
    Volunteers
    139 people
    Sponsor
    National Cancer Institute (NCI)
    Can I take part? NCT07619534

  • Metastatic Solid Tumor, Recurrent Solid Tumor

    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    • Recruiting
    • Age: 18 years and older
    • Phase 1
    • Injection or infusion

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.

    Conditions
    Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
    Trial name
    NEXUS-01 (NCT06465069)
    Testing
    LY4052031, Pembrolizumab
    Where
    39 sites in United States, Australia and 6 more
    Volunteers
    460 people
    Sponsor
    Eli Lilly and Company
    Can I take part? NEXUS-01

  • Triple-Negative Breast Cancer (TNBC)

    Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 1/2

    This study is a phase I/II open-label randomized clinical trial to examine whether administration of isunakinra (EBI-005), a modified recombinant IL1 receptor antagonist, can sensitize human TNBC to the PD1…

    Trial name
    NCT07698106
    Testing
    Group 1-Isunakinra
    Volunteers
    60 people
    Sponsor
    University Health Network, Toronto
    Can I take part? NCT07698106

  • Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)

    A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

    • Recruiting
    • Age: 18 years and older
    • Phase 1
    • Pill or oral medicine

    This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…

    Conditions
    Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
    Trial name
    Luca-1 (NCT07705334)
    Testing
    SHY-ONC6
    Where
    3 sites in United States
    Volunteers
    30 people
    Sponsor
    SHY Therapeutics
    Can I take part? Luca-1

  • Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative

    Intratumoral N17350 in Advanced Solid Tumors

    • Recruiting
    • Age: 18 years and older
    • Phase 1/2

    The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies.

    Conditions
    Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
    Trial name
    OP-NEU-101 (NCT07339176)
    Testing
    N17350
    Where
    9 sites in United States, Australia
    Volunteers
    275 people
    Sponsor
    Onchilles Pharma Inc
    Can I take part? OP-NEU-101

  • Triple-Negative Breast Cancer (TNBC)

    Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast Cancer

    • Not yet recruiting
    • Age: 18 years and older
    • Medical device

    This randomized, multicenter, open-label clinical study will evaluate whether adding the Fasten Onco digital therapy, which supports a fasting-mimicking diet (FMD), to standard neoadjuvant treatment can reduce treatment-related…

    Trial name
    FAST-01 (NCT07884721)
    Testing
    Fasten Onco, Standard Neoadjuvant Treatment
    Where
    7 sites in France
    Volunteers
    144 people
    Sponsor
    FASTEN
    Can I take part? FAST-01

  • Breast Cancer, TNBC - Triple-Negative Breast Cancer

    Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment

    • Not yet recruiting
    • Age: 18 to 70 years
    • Phase 2
    • Injection or infusion

    This is a prospective, open-label, single-center, phase II, randomized controlled clinical trial involving patients with triple-negative breast cancer who meet the criteria for neoadjuvant chemotherapy (T > 2 cm, N+).

    Conditions
    Breast Cancer, TNBC - Triple-Negative Breast Cancer, Immunotherapy
    Trial name
    NCT07884201
    Testing
    Thymalfasin
    Volunteers
    572 people
    Sponsor
    Fudan University
    Can I take part? NCT07884201

Completed, with results posted

All –

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in